Nadav Ahituv

Nadav Ahituv (Hebrew: נדב אחיטוב) is the Director for the Institute for Human Genetics at the University of California, San Francisco (USCF).^[1][2][3] He is also a Professor in the Department of Bioengineering and Therapeutic Sciences and leads the Ahituv Lab at University of California, San Francisco (USCF).^[1][4]

Early life and education

Ahituv received his PhD with distinction in human genetics from Tel-Aviv University, where he worked on hereditary hearing loss.^[1][3][2]

Research

Ahituv developed cis-regulation therapy (CRT) for genetic diseases that are caused due to changes in gene dosage ^[5][6] and adipose manipulation transplantation (AMT) that engineers fat cells and implants them for therapeutic benefits.^[7]

The Ahituv Lab investigates gene regulatory elements and their relationship to human diversity and disease.^[4] His lab also focuses on identifying gene regulatory elements and linking nucleotide variation within them to various phenotypes, including morphological differences between species, drug response, and human disease.^[8] The lab is one of the developers of massively parallel reporter assays (MPRAs) that allow for high-throughput functional characterization of gene regulatory elements.^[9]

Awards and honors

In 2014, Ahituv received the ASCPT Leon I. Goldberg young investigator award from The American Society for Clinical Pharmacology and Therapeutics.^[10][1] In 2024, Ahituv received the Scientific Achievement Award from The American Society of Human Genetics (ASHG).^[11]